Abstract
Almost 10% of the world’s population is affected by alcohol use disorder (AUD). The combination between psychosocial intervention and pharmacological treatment seems to be the most effective approach for patients affected by AUD. Among effective drugs useful in the treatment of AUD, GABAB-ergic medications have been tested with encouraging results (i.e. sodium oxybate, baclofen, gabapentin, pregabalin and tiagabine). The present review will summarize available data on these medications.
Keywords: Alcohol use disorder, craving, GABAB agonists, pharmacological treatment.
Current Pharmaceutical Design
Title:GABAB Agonists for the Treatment of Alcohol Use Disorder
Volume: 21 Issue: 23
Author(s): Antonio Mirijello, Fabio Caputo, Gabriele Vassallo, Benjamin Rolland, Claudia Tarli, Antonio Gasbarrini and Giovanni Addolorato
Affiliation:
Keywords: Alcohol use disorder, craving, GABAB agonists, pharmacological treatment.
Abstract: Almost 10% of the world’s population is affected by alcohol use disorder (AUD). The combination between psychosocial intervention and pharmacological treatment seems to be the most effective approach for patients affected by AUD. Among effective drugs useful in the treatment of AUD, GABAB-ergic medications have been tested with encouraging results (i.e. sodium oxybate, baclofen, gabapentin, pregabalin and tiagabine). The present review will summarize available data on these medications.
Export Options
About this article
Cite this article as:
Mirijello Antonio, Caputo Fabio, Vassallo Gabriele, Rolland Benjamin, Tarli Claudia, Gasbarrini Antonio and Addolorato Giovanni, GABAB Agonists for the Treatment of Alcohol Use Disorder, Current Pharmaceutical Design 2015; 21 (23) . https://dx.doi.org/10.2174/1381612821666150619091858
DOI https://dx.doi.org/10.2174/1381612821666150619091858 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Enhancing Central Nervous System Endogenous GLP-1 Receptor Pathways for Intervention in Alzheimers Disease
Current Alzheimer Research Modulation of Midbrain Dopamine Neurotransmission by Serotonin, a Versatile Interaction Between Neurotransmitters and Significance for Antipsychotic Drug Action
Current Neuropharmacology Aspartame: Should Individuals with Type II Diabetes be Taking it?
Current Diabetes Reviews A Proteomics Perspective: From Animal Welfare to Food Safety
Current Protein & Peptide Science ThermoTRP Channels in Nociceptors: Taking a Lead from Capsaicin Receptor TRPV1
Current Neuropharmacology Regulation of Angiotensin II Receptor Expression
Current Pharmaceutical Design Subclinical Thyroid Dysfunction and the Risk of Cardiovascular Disease
Current Pharmaceutical Design Pharmacological Effects of Turmeric on Learning, Memory and Expression of Muscarinic Receptor Genes (M1, M3 and M5) in Stress-induced Mouse Model
Current Drug Targets Insulin Treatment and Weight Gain in Type 2 Diabetes: Is Our Knowledge Complete?
Current Nutrition & Food Science Metabotropic Glutamate Receptor 7: From Synaptic Function to Therapeutic Implications
Current Neuropharmacology Neurohormonal Activation in Ischemic Stroke: Effects of Acute Phase Disturbances on Long-Term Mortality
Current Neurovascular Research Current Approaches for the Treatment with Thyroid Hormone Analogs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Editorial
Recent Patents on CNS Drug Discovery (Discontinued) Obesity: The Metabolic Disease, Advances on Drug Discovery and Natural Product Research
Current Topics in Medicinal Chemistry Treatment of Obesity: Should We Target the Individual or Society?
Current Pharmaceutical Design Inflammatory Responses in Brain Ischemia
Current Medicinal Chemistry Protein-Energy Malnutrition Alters Hippocampal Plasticity-Associated Protein Expression following Global Ischemia in the Gerbil
Current Neurovascular Research Epigenetics in Alzheimers Disease: a Focus on DNA Modifications
Current Pharmaceutical Design Histamine H3 Antagonists as Wake-Promoting and Pro-Cognitive Agents
Current Topics in Medicinal Chemistry FoxO1 Inhibitors: The Future Medicine for Metabolic Disorders?
Current Diabetes Reviews